MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Cambridge Healthtech Institute
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

CHI’s 2nd Annual Targeting Cancer Stem Cells Symposium, February 11-12, 2013 in San Francisco, California - Latest speaker confirmed: John S. Yu, M.D., Professor & Vice Chairman, Neurosurgery, Cedars-Sinai Medical Center; Chairman & CSO, ImmunoCellular Therapeutics - TriConference.com / CHICorporate.com
CHI’s 2nd Annual Targeting Cancer Stem Cells Symposium, February 11-12, 2013 in San Francisco, California

 

NewswireToday - /newswire/ - Needham, MA, United States, 2012/10/24 - Latest speaker confirmed: John S. Yu, M.D., Professor & Vice Chairman, Neurosurgery, Cedars-Sinai Medical Center; Chairman & CSO, ImmunoCellular Therapeutics - TriConference.com / CHICorporate.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

CHI’s 2nd annual Targeting Cancer Stem Cells: Promising New Therapeutics for Oncology symposium will once again be a part of the Molecular Medicine Tri-Conference taking place at the Moscone North Convention Center in San Francisco, CA. Presentations will highlight achievements in basic science enhancing our understanding of cancer stem cells, and advances in the discovery and development of novel therapeutics making their way to the clinic. Presentations will focus on the unique challenges of working with CSCs, from characterizing cell populations to the development of screening assays, identification of druggable targets and pathways, validation in pre-clinical models, and translation to the clinic.

CHI just confirmed the participation of Dr. John S. Yu (Cedars-Sinai Medical Center / ImmunoCellular Therapeutics) who will deliver a presentation on “Active Immunotherapy for Cancer Stem Cells.” ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company focused on developing products for the treatment of brain and other cancers that harness the native immune system to attack CSCs without harming healthy tissue. ImmunoCellular has commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma.

Dr. Yu is a member of the full-time faculty in the Department of Neurosurgery at Cedars-Sinai Medical Center. An internationally renowned neurosurgeon, Dr. Yu's clinical focus is on the treatment of malignant and benign brain and spinal tumors. He is also conducting extensive research in immune and gene therapy for brain tumors. He has also done extensive research in the use of neural stem cells as delivery vehicles for brain cancers and neurodegenerative diseases. He was inducted into Castle and Connelly's America's Top Doctors in 2005. Dr. Yu has published articles in a number of prestigious journals, including The Lancet, Cancer Research, Cancer Gene Therapy, Human Gene Therapy, Journal of Neuroimmunology, Journal of Neurological Science and Journal of Neurosurgery.

Additional companies presenting:

• Cellerant Therapeutics, Inc.
• Dainippon Sumitomo Pharma Group
• ETH Zurich
• Genentech, Inc.
• Macrogenics, Inc.
• McMaster University
• OncoMed Pharmaceuticals
• Pfizer
• The Mount Sinai School of Medicine
• Sanford Consortium for Regenerative Medicine & Moores UC San Diego Cancer Center
• University of California Los Angeles
• University of Michigan Comprehensive Cancer Center
• University of Texas Southwestern Medical Center
• Verastem, Inc.

To view the agenda and to register, please visit TriConference.com/.

About Cambridge Healthtech Institute (CHI)
Cambridge Healthtech Institute (chicorporate.com) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Cambridge Healthtech Institute

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


CHI’s 2nd Annual Targeting Cancer Stem Cells Symposium, February 11-12, 2013 in San Francisco, California

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: James Prudhomme - HealthTech.com 
781-972-5400 reg[.]healthtech.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Cambridge Healthtech Institute securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Cambridge Healthtech Institute / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  BizJobs.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)